IP Library Patent Application 17845481
Patent Application
App. No. 17/845,481

DETECTION OF COLORECTAL CANCER

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
17/845,481
Abstract

The present disclosure provides, among other things, methods for colorectal cancer screening and compositions related thereto. In various embodiments, the present disclosure provides methods for colorectal cancer screening that include analysis of methylation status of one or more methylation biomarkers, and compositions related thereto. In various embodiments, the present disclosure provides methods for colorectal cancer screening that include screening methylation status of one or more methylation biomarkers in cfDNA, e.g., in ctDNA. In various embodiments, the present disclosure provides methods for colorectal cancer screening that include screening methylation status of one or more methylation biomarkers in cfDNA, e.g., in ctDNA, using MSRE-qPCR.

Claims (18)

1 . A method of screening for colorectal cancer, the method comprising determining the methylation status of at least one DMR of LONRF2, at least one DMR of PDGFD, and at least one DMR of FGF14

in DNA of a human subject, wherein the DNA is cell-free DNA of the human subject, and diagnosing colorectal cancer in the subject.

2 .- 3 . (canceled)

4 . The method of claim 1 , the method comprising determining whether the one or more methylation loci are hypermethylated as compared to a reference, wherein hypermethylation is indicative of colorectal cancer.

5 .- 9 . (canceled)

10 . The method of claim 1 , wherein the method comprises determining the methylation status of DMR FGF14 '577.

11 . The method of claim 1 , wherein the method comprises determining the methylation status of DMR PDGFD '388.

12 .- 14 . (canceled)

15 . The method of claim 1 , wherein one or more of the DMRs are amplified by oligonucleotide primer pairs provided in Table 13.

16 . The method of claim 1 , wherein the DNA is isolated from blood, plasma, urine, saliva, or stool of the human subject.

17 .- 29 . (canceled)

30 . The method of claim 1 , wherein methylation status is determined using one or more members selected from the group consisting of methylation sensitive restriction enzyme quantitative polymerase chain reaction (MSRE-qPCR), Methylation-Specific PCR, Methylation Specific Nuclease-assisted Minor-allele Enrichment PCR, and next-generation sequencing.

31 .- 41 . (canceled)

42 . The method of claim 1 , wherein the method comprises determining the methylation status of DMR PDGFD '921.

43 . The method of claim 1 , wherein the method comprises determining the methylation status of DMR LONRF2 '387.

44 . The method of claim 1 , wherein the method comprises determining the methylation status of at least one DMR of CNRIP1.

45 . The method of claim 44 , wherein the method comprises determining the methylation status of at least one of the following DMRs: CNRIP1 '272 and CNRIP1 '232.

46 . The method of claim 1 , wherein methylation status is determined using massively parallel sequencing.

Assignments (4)
CHANGE OF NAME Recorded Aug 1, 2023
From: UNIVERSAL DIAGNOSTICS, S.L.
To: UNIVERSAL DIAGNOSTICS, S.A.
Reel/Frame 064461/0001 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 11, 2022
From: CHERSICOLA, MARKO; KNAP, PRIMOZ
To: GENEPLANET D.O.O.
Reel/Frame 061741/0563 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 11, 2022
From: GENEPLANET D.O.O.
To: UNIVERSAL DIAGNOSTICS, S.L.
Reel/Frame 061741/0622 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 11, 2022
From: BITENC, MARKO; KRUUSMAA, KRISTI; MARTINEZ-BAREA, JUAN; HENSE, CHRISTIAN
To: UNIVERSAL DIAGNOSTICS, S.L.
Reel/Frame 061741/0648 →